PYC Therapeutics Ltd

PYC Therapeutics reported adjusted EPS of -$0.0233 versus an expected -$7.60 and revenue of $28.64 million, meaning the results significantly beat estimates. Management emphasized the shift to advanced clinical development, with the ADPKD program PYC-003 in focus (13 of 24 patients enrolled) and multiple human data readouts expected by 2027. PYC says it has sufficient funds to finance several programs and is preparing for a possible U.S. dual listing. The stock reacted positively after hours and traded near its 52-week high. » More on de.investing.com

PYC Therapeutics has raised AUD 600–650m, boosting its liquidity runway to over AUD 750m and materially strengthening the balance sheet. The financing, which included AUD 333.3m from tier‑1 investors, enables the company to advance its four pipeline programs into late‑stage development without further capital raises. Management issues EPS guidance of $0.23 for 2025 and $1.78 for 2026 and revenue guidance of $84.77m and $283.49m, respectively, while emphasizing continued strategic flexibility. Risks remain around clinical timelines, regulatory hurdles and competitive pressure. » More on de.investing.com

Analysts covering PYC Therapeutics expect a final loss in 2027 and forecast the company to generate AU$100m in profit in 2028, implying an average annual growth rate of about 28%. The AU$994m market-cap biotech reported a AU$50m loss for the year to 30 June 2025. PYC Therapeutics has no debt on its balance sheet, lowering financial risk despite ongoing cash burn. The projection depends on continued strong growth and typical biotech development progress, so timelines could slip if targets are missed. » More on finance.yahoo.com